Клиномир в тестовом запуске. Кто с нами с первых дней, получит отметку «С первых дней» в профиле и первым увидит новые возможности сайта.

Зарегистрироваться
Прекращено Фаза III Россия

ampreloxetine; Placebo

A Phase 3, 22-week, Multi-center, Randomized Withdrawal Study of TD-9855 in Treating Symptomatic Neurogenic Orthostatic Hypotension in Subjects With Primary Autonomic Failure

Номер протокола0170
ФазаФаза III
Участников по плану — во всех странах исследования203
Сроки22.02.2019 — 10.11.2021
Начало: 22 февраля 2019Окончание: 10 ноября 2021
Плановый срок исследования истёк

Постоянная ссылка: https://clinomir.ru/trials/nct/NCT03829657/

Источник: ClinicalTrials.gov (U.S. National Library of Medicine). Что откуда

Простыми словами

Словарь терминов
  • Фаза III — большое исследование: новый препарат сравнивают со стандартным лечением или плацебо, чтобы доказать пользу и безопасность.
  • Исследование прекращено досрочно, новых участников не набирают.
  • Возраст участников: от 30 лет. Остальные условия — в блоке «Кто может участвовать».
  • По плану участвуют 203 чел. во всех странах исследования.
  • Центров в реестре: 6 в 3 городах. Список — ниже на странице.
  • Плановая дата окончания (11.2021) уже прошла.

Пересказ собран автоматически из данных реестра, без оценки пользы и рисков. Подробно о рисках и пользе рассказывает врач центра перед подписанием согласия.

Кто может участвовать

Возрастот 30 лет
ПолЛюбой
Здоровые добровольцынет
Полный текст критериев (на английском, как в ClinicalTrials.gov) · включение: 11 · невключение: 22

Критерии включения

  • (For 0169 Completers Group):
  • Subject has completed 4 weeks of double blind treatment in Study 0169 (V6) and, in the opinion of the Investigator, could benefit from continued treatment with ampreloxetine. Only subjects with OHSA#1 score of ≤7 will be eligible for randomization for the double-blind treatment period.
  • Subject has a minimum of 80% study medication compliance in Study 0169.
  • Inclusion Criteria (For De Novo Group):
  • Subject is male or female and at least 30 years old.
  • Subject must meet the diagnostic criteria of symptomatic nOH, as demonstrated by a sustained reduction in BP of ≥20 mm Hg (systolic) or ≥10 mm Hg (diastolic) within 3 min of being tilted-up ≥60o from a supine position as determined by a tilt-table test.
  • Subject must score at least a 4 on the OHSA#1 at V1.
  • For subjects with PD only: Subject has a diagnosis of PD according to the United Kingdom Parkinson's Disease Society (UKPDS) Brain Bank Criteria (1992).
  • For subjects with MSA only: Subject has a diagnosis of possible or probable MSA of the Parkinsonian subtype (MSA-P) or cerebellar subtype (MSA-C) according to The Gilman Criteria (2008).
  • For subjects with PAF only: Subject has documented impaired autonomic reflexes, including the Valsalva maneuver performed within 24 months from the date of randomization
  • Subject has plasma Norepinephrine (NE) levels ≥ 100 pg/mL after being in seated position for 30 minutes.

Критерии невключения

  • (For 0169 Completers Group):
  • Subject has a medical, laboratory, or surgical issue(s) deemed by the investigator to be clinically significant.
  • Subject has an uncooperative attitude or reasonable likelihood of non-compliance with the protocol.
  • Subject has a concurrent disease or condition that, in the opinion of the investigator, would confound or interfere with study participation or evaluation of safety, tolerability, or pharmacokinetics of the study drug.
  • Exclusion Criteria (For De Novo Group):
  • Subject has a known systemic illness known to produce autonomic neuropathy, including but not limited to amyloidosis, and autoimmune neuropathies.
  • Subject has a known intolerance to other NRIs or serotonin norepinephrine reuptake inhibitors (SNRIs).
  • Subject currently uses concomitant antihypertensive medication for the treatment of essential hypertension unrelated to autonomic dysfunction.
  • Subject has used strong CYP1A2 inhibitors or inducers within 7 days or 5 half-lives, whichever is longer, prior to V1 or requires concomitant use until the follow-up visit.
  • Subject has changed dose, frequency, or type of prescribed medication for orthostatic hypotension within 7 days prior to V1.
  • Midodrine and droxidopa (if applicable) must be tapered off at least 7 days prior to V1.
  • Subject has known or suspected alcohol or substance abuse within the past 12 months (Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision \[DSM-IV-TR®\] definition of alcohol or substance abuse).
  • Subject has a clinically unstable coronary artery disease, or has had a major cardiovascular or neurological event in the past 6 months.
  • Subject has used any monoamine oxidase inhibitor (MAO-I) within 14 days prior to V1.
  • Subject has a history of untreated closed angle glaucoma, or treated closed angle glaucoma that, in the opinion of an ophthalmologist, might result in an increased risk to the subject.
  • Subject has any significant uncontrolled cardiac arrhythmia.
  • Subject has a Montreal Cognitive Assessment (MoCA) ≤23.
  • Subject is unable or unwilling to complete all protocol specified procedures including questionnaires.
  • Subject had a myocardial infarction in the past 6 months or has current unstable angina.
  • Subject has known congestive heart failure (New York Heart Association \[NYHA\] Class 3 or 4).
  • Subject has a clinically significant abnormal laboratory finding (e.g., alanine aminotransferase \[ALT\] or aspartate aminotransferase \[AST\] >3.0 x upper limit of normal \[ULN\]; blood bilirubin \[total\] >1.5 x ULN; estimated glomerular filtration rate (eGFR) <30 mL/min/1.73 m2, or any abnormal laboratory value that could interfere with safety of the subject).
  • Subject has demonstrated a history of lifetime suicidal ideation and/or suicidal behavior, as outlined by the Columbia Suicide Severity Rating Scale (C-SSRS)(Baseline/Screening Version). Subject should be assessed by the rater for risk of suicide and the subject's appropriateness for inclusion in the study.

Источник: ClinicalTrials.gov, NCT03829657 · запись обновлена в реестре 20 января 2023.

Дизайн и результаты

ДизайнРандомизированное, тройное слепое, параллельные группы; цель — лечение
Включено участников (факт, все страны)203
Почему остановлено (как в реестре): Stopped early due to company decision. Company decision based on analysis results in TD-9855-0169.
Что измеряют — первичные конечные точки (1)
  • Proportion of Participants With Treatment Failure at Week 6 of RW Treatment Period — 6-week randomized withdrawal period (Week 16 to Week 22)

Цель исследования

A Phase 3, 22-week, Multi-center, Randomized Withdrawal Study of ampreloxetine in Treating Symptomatic Neurogenic Orthostatic Hypotension in Subjects with Primary Autonomic Failure

Где проходит

6 центров в 3 городах

Откуда эта информация

  • ClinicalTrials.gov (U.S. National Library of Medicine) · NCT03829657 Официальный реестр (США) · загружено 9 ноября 2026
    Препарат, номер протокола, название, цель, фаза, статус, сроки, число участников, спонсор, центры

Сведения сведены и нормализованы порталом «Клиномир»: названия компаний и центров приведены к одному написанию. Нашли ошибку? Напишите нам — исправим.

Изменения не сохранены

На этой странице есть несохранённые изменения. Если уйти со страницы, они пропадут.